Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ZS Pharma
San Mateo, California, USAzspharma.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
ZS Pharma developed ZS‑9, a potential best-in-class treatment for hyperkalemia using proprietary ion-trap technology. Clinical trials demonstrated strong efficacy and safety. At the time of its acquisition by AstraZeneca in late 2015, the drug was under regulatory review with anticipated approval and market launch in mid-to-late 2016. The company had rapidly advanced from founding to IPO to late-stage clinical development within seven years.
- Therapeutic areas
- Nephrology
- Modalities
- Small molecules (specifically ion-trap technology for potassium binding)
- Industry
- Biotech
02
Partnerships
UNT Health Science Center Accelerator Lab ProgramTech Fort Worth incubator support during early years
Beyond the preview
Go deeper on ZS Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZS Pharma.